1. Home
  2. COE vs BOLD Comparison

COE vs BOLD Comparison

Compare COE & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo 51Talk Online Education Group

COE

51Talk Online Education Group

BUY

Current Price

$11.46

Market Cap

68.1M

Sector

Real Estate

ML Signal

BUY

Logo Boundless Bio Inc.

BOLD

Boundless Bio Inc.

HOLD

Current Price

$2.38

Market Cap

60.8M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
COE
BOLD
Founded
2011
2018
Country
Singapore
United States
Employees
N/A
N/A
Industry
Other Consumer Services
Sector
Real Estate
Exchange
Nasdaq
Nasdaq
Market Cap
68.1M
60.8M
IPO Year
2015
2024

Fundamental Metrics

Financial Performance
Metric
COE
BOLD
Price
$11.46
$2.38
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
26.0K
★ 196.7K
Earning Date
12-07-2026
11-04-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 32.47
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$70.66
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$9.93
$0.96
52 Week High
$52.00
$3.16

Technical Indicators

Market Signals
Indicator
COE
BOLD
Relative Strength Index (RSI) 48.92 36.03
Support Level $9.95 $1.40
Resistance Level $12.48 $2.71
Average True Range (ATR) 0.84 0.16
MACD 0.22 -0.00
Stochastic Oscillator 68.34 19.77

Price Performance

Historical Comparison
COE
BOLD

About COE 51Talk Online Education Group

51 Talk Online Education Group is an online education platform in China, with core expertise in English education. The company's mission is to make quality education accessible and affordable. It's online and mobile education platforms enable students across China to take live interactive English lessons with overseas foreign teachers, on demand. The Group operates in geographical areas: Asia-Pacific region; and Other areas, of which it derives maximum revenue from Asia-Pacific.

About BOLD Boundless Bio Inc.

Boundless Bio Inc is a clinical-stage oncology company. It is focused on developing cancer therapeutics that address the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Using its proprietary Spyglass platform, the company identifies targets essential for ecDNA functionality, then designs and develops small-molecule drugs called ecDNA-directed therapies (ecDTx) to inhibit those targets. Its main ecDTx candidate under development, BBI-940, is a novel, oral, selective degrader that has demonstrated potent anti-tumor activity across a range of cancer cell lines and mouse xenograft models, including single-agent tumor regressions.

Share on Social Networks: